<DOC>
	<DOCNO>NCT02500108</DOCNO>
	<brief_summary>The purpose study ass risk serious cardiac event , specifically ventricular tachyarrhythmia sudden cardiac death ( VT/SCD ) , associate use domperidone population patient Parkinson 's disease . The hypothesis study risk VT/SCD high among domperidone user , especially high dose . The investigator conduct retrospective population-based cohort study use health care databases eight jurisdiction Canada UK . The study cohort define initiation new antiparkinsonian drug new diagnosis Parkinson 's disease . The result separate site combine meta-analysis provide overall assessment risk VT/SCD user domperidone .</brief_summary>
	<brief_title>Domperidone Risk Sudden Cardiac Death</brief_title>
	<detailed_description>The purpose study ass risk serious cardiac event associate use domperidone cohort patient Parkinson 's disease . More specifically , study objective ass risk ventricular tachyarrhythmia sudden cardiac death associate use domperidone compare use patient Parkinson 's disease . In addition , investigator would also like determine whether risk ventricular arrhythmia sudden cardiac death increase dose domperidone patient Parkinson 's disease . The investigator use common-protocol approach conduct retrospective cohort study use health care data eight jurisdiction ( Canadian province Alberta , British Columbia , Manitoba , Nova Scotia , Ontario , Quebec , Saskatchewan , well United Kingdom ( UK ) Clinical Practice Research Datalink [ CPRD ] ) . The Canadian database contain population-level data physician billing , diagnose procedure hospital discharge abstract , vital statistic , dispensation prescription drug . The CPRD clinical database representative UK population contains record patient see 680 general practitioner practice UK ; data link Hospital Episode Statistics ( HES ) database , contain in-hospital diagnosis procedure data . Study Population In jurisdiction , investigator assemble study cohort include patient new diagnosis Parkinson 's disease first-ever prescription antiparkinsonian drug January 1 , 1990 ( 1 year site-specific data available , whichever later ) June 30 , 2012 . Patients follow date study cohort entry occurrence either study endpoint ( define ) censor due death , departure database , loss continuous health plan drug plan enrolment , entry long-term care facility , end study period ( last date data availability site ) , whichever occur first . Data Alberta , Ontario , Nova Scotia restrict patient age 66 year old prescription data available young patient . Case-control selection The cohort define analyzed use nested case-control approach , case define first diagnosis ventricular tachyarrhythmia ( VT ) sudden cardiac death ( SCD ) time cohort entry . For case , 30 control randomly select among cohort member risk set define case , match age , sex , date cohort entry ( Â±1 year ) , duration follow-up . Matching duration follow-up ( i.e. , best estimate duration disease ) serve proxy control potential confounding progression severity Parkinson 's disease . Exposure Assessment The clinically relevant exposure period consider data analysis year precede index date , exposure domperidone classify accord prescription dispensed time period . For case match control , investigator identify prescription domperidone computerized medical record year prior index date . Current exposure domperidone define prescription dispense within 30 day index date ( 35 day Saskatchewan ) . Recent use , past use , use also explore mutually exclusive exposure category . Recent use define prescription dispense 31 90 day index date , past use prescription dispense 91 365 day index date . No use define prescription domperidone year precede index date reference category . Statistical analysis Conditional logistic regression use estimate odds ratios correspond 95 % confidence interval ( CIs ) association domperidone use risk VT/SCD . In secondary analysis , VT/SCD analyze accord duration domperidone use ( &lt; =30 day , &gt; 30 day ) , daily dose domperidone ( &lt; =30 mg per day , &gt; 30 mg per day ) . In addition , several sensitivity analysis conduct , define priori , assess robustness result . Finally , site-specific estimate meta-analyzed use fixed random effect model . The amount between-site heterogeneity estimate use I square statistic .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Death</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<mesh_term>Domperidone</mesh_term>
	<criteria>Patients diagnosis Parkinson 's disease prescription antiparkinsonian drug , least 365 day information database prior cohort entry . Age &lt; 50 cohort entry date ; age &lt; 66 database senior Missing gender Less 1 year provincial Medicare enrollment equivalent enrollment CPRD precede cohort entry Patients long term care facility Diagnosis PD dispensing ( prescription CPRD ) antiparkinsonian drug year precede cohort entry Patients prescription antiparkinsonian drug without diagnosis Parkinson 's disease another indication atypical Parkinsonism secondary Parkinsonism , restless legs syndrome , hyperprolactinemia , acromegaly year cohort entry All patient prescription domperidone year cohort entry All patient history ventricular tachyarrhythmia , abort cardiac arrest , implantation cardiac defibrillator , cancer nonmelanoma skin cancer Cohort entry date cohort exit date ( followup )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Domperidone</keyword>
	<keyword>Ventricular Tachyarrhythmia</keyword>
	<keyword>Sudden cardiac death</keyword>
	<keyword>Pharmacotherapy</keyword>
	<keyword>Adverse event</keyword>
</DOC>